Director/PDMR Shareholding
RNS Number : 0033ZGSK PLC14 October 2026GSK plc (the ‘Company’)
Transaction notification
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Luke Miels
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
756
£17.3550
379
£17.3550
278
d)
Aggregated information
Aggregated volume Price
1,413
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Julie Brown
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
607
£17.3550
707
£17.3550
549
d)
Aggregated information
Aggregated volume Price
1,863
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
406
£17.3550
246
£17.3550
131
d)
Aggregated information
Aggregated volume Price
783
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Shobie Ramakrishnan
b)
Position/status
Chief Digital and Technology Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
ISIN: US37733W2044
b)
Nature of the transaction
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 8 October 2026 on ADS held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5400
188
$46.5400
113
$46.5400
63
d)
Aggregated information
Aggregated volume Price
364
$46.5400
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
David Redfern
b)
Position/status
President, Corporate Development
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
481
£17.3550
219
£17.3550
194
d)
Aggregated information
Aggregated volume Price
894
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
579
£17.3550
321
£17.3550
203
d)
Aggregated information
Aggregated volume Price
1,103
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
324
£17.3550
195
£17.3550
141
d)
Aggregated information
Aggregated volume Price
660
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
501
£17.3550
302
£17.3550
184
d)
Aggregated information
Aggregated volume Price
987
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Tony Wood
b)
Position/status
Chief Scientific Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
618
£17.3550
281
£17.3550
258
d)
Aggregated information
Aggregated volume Price
1,157
£17.3550
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Maya Martinez-Davis
b)
Position/status
President, US
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.5400
179.308
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them (‘PCA’)
a)
Name
Julie Brown
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£17.3550
2,409.639
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2026-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHFFLFLLEMSEES
